Video Series

A panel of experts reviews the emerging interchangeable biosimilars and best practices on how to educate providers and patients on these treatment options.

Maia Kayal, MD, MS, and Jonathan Kay, MD, define interchangeability and review the details of a switching study.

Carlos Larrauri, APRN, details the signs and symptoms necessary to make a schizophrenia diagnosis.

John J. Miller, MD, and Nev Jones, PhD, open a discussion providing an overview on the current state of patients with schizophrenia.

With their final thoughts, the panelists emphasize patient-centered care is at the forefront of critical MS treatment considerations for providers.

A comprehensive look into MS treatment objectives is provided.

Panelists provide their closing thoughts on optimizing the management of HIV.

The panel of experts discusses emerging and anticipated changes to the HIV treatment landscape.

A discussion surrounding clinical trials in multiple sclerosis is led by Dr Haumschild.

The panel expands on the role of BTK inhibitors in the MS treatment landscape.

The panel discusses unmet needs that remain in the treatment and management of HIV.

Dr Welch leads a discussion on collaborations between payers, patients, and providers to optimize the care of patients with HIV.

In their closing thoughts, the panelists provide their key takeaways regarding immunizing against RSV.

BTK inhibitor implementation for MS treatment is explored.

The panelists provide insights into the decision-making process behind switching MS treatment strategies due to lacking or failed therapies.

Key opinion leaders discuss the value of real-world evidence in the management of HIV.

Assessing the quality of an HIV treatment plan is crucial to patient prognosis.

In her closing thoughts, Dr Filer provides insights into the unmet needs in the treatment of RSV.

Discussion surrounding promotion of RSV vaccine awareness is further discussed.

The panel offers strategies for being proactive .

Dr Haumschild leads a discussion surrounding patient and provider collaboration to avoid clinical inertia in MS treatment pathways.

Frontline treatment options and the benefits of early intervention of MS are illustrated.

Medical experts discuss the significance of pill burden in the HIV treatment pathway.

The role of and indication for long-acting injectables is highlighted as a treatment approach for HIV.

Experts discuss the financial needs for RSV vaccines through a payer lens.

Financial burden associated with RSV treatment is explored by a medical expert.

Experts highlight the potential obstacles for RSV vaccines.

Key opinion leaders highlight the MS treatment landscape.

An expert panel discusses cost burden associated with the treatment of MS.

The panelists provide their final thoughts regarding disparities in women’s health.